FDA clears generic HIV shot for global rollout at $40 annual cost

Key points

• FDA approved Dr. Reddy’s generic lenacapavir under a tentative designation, allowing U.S. government procurement and speeding up approvals in other nations.
• The generic will cost $40 per person per year in 120 low- and middle-income countries, aligning with the cost of daily oral PrEP.
• Lenacapavir requires only two injections per year and demonstrated near-total efficacy in preventing new infections in high-risk populations.
• The brand-name version, Yeztugo, remains protected by patent in the U.S. with a list price of $28,218 annually.
• Initial supplies are expected to reach countries by late 2026, with wider distribution in 2027, though some nations must undergo their own regulatory reviews.

Background

Lenacapavir was approved as a brand-name drug in June 2025, with earlier trials showing zero infections in a 2024 study of over 2,000 women in South Africa and Uganda. Previous coverage noted that while the drug is highly effective, access barriers persisted, including high U.S. prices and exclusions of 26 middle-income countries from generic licensing deals. International HIV funding also saw an 18% drop in 2025, complicating efforts to scale prevention tools. The current approval builds on voluntary licensing agreements established in late 2024 between Gilead Sciences and six generic manufacturers, including Dr. Reddy’s, to facilitate production in sub-Saharan Africa, Asia, and Latin America.

How outlets are covering it

AP News highlights the affordability and convenience of the generic, noting that the $40 annual cost matches daily pills while requiring far fewer doses. STAT emphasizes the speed of the regulatory process, describing the 16-month timeline from brand-name to generic approval as a significant acceleration compared to typical decades-long delays. Unitaid, a key partner in the effort, frames the approval as a milestone but warns that an affordable drug alone is insufficient; they stress the need for robust health systems, provider training, and community engagement to ensure equitable access. All sources agree that the generic will not be available in the U.S. due to patent protections but will significantly impact global access. Gilead Sciences supports the move, stating it enables the fastest path to expanding access for communities most affected by HIV.

Why it matters

This approval addresses a critical gap in HIV prevention for the 20 million people globally who need PrEP but lack access to affordable options. By reducing the cost to $40 per year and simplifying administration to twice-yearly injections, the generic could dramatically improve adherence and coverage in low- and middle-income countries. It also sets a precedent for faster generic approvals of complex injectables, potentially transforming how new HIV treatments reach vulnerable populations. However, the impact depends on subsequent funding and health system readiness, as noted by experts who warn that approval is only the first step in achieving widespread access.

What to watch

Dr. Reddy’s plans to begin shipping the generic next month, with initial supplies reaching countries by the end of 2026. Broader availability is expected in 2027, contingent on national regulatory approvals in some regions. Partners including Unitaid, Wits RHI, and the Clinton Health Access Initiative are working with governments and the Global Fund to support country introduction and community engagement. Other generic manufacturers have yet to receive FDA approval, and advocates are calling for increased funding to purchase and distribute the drug to all who need it. The next phase will focus on generating real-world evidence to optimize delivery to diverse and underserved populations.